PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Titel:
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Auteur:
Buteau, James P Martin, Andrew J Emmett, Louise Iravani, Amir Sandhu, Shahneen Joshua, Anthony M Francis, Roslyn J Zhang, Alison Y Scott, Andrew M Lee, Sze-Ting Azad, Arun A McJannett, Margaret M Stockler, Martin R Williams, Scott G Davis, Ian D Hofman, Michael S